Board Member
MBX Biosciences, Inc. (MBX)Equibles does not estimate personal net worth.
Get an email with a short summary when MBX Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get MBX alertsP. Kent Hawryluk is recorded as Board Member at MBX Biosciences, Inc. (MBX). MBX Biosciences, Inc. reported in an 8-K filed June 6, 2025 that P. Kent Hawryluk was appointed Class I director, effective June 5, 2025. The proxy statement of MBX Biosciences, Inc. reports total compensation of $2,990,867 for P. Kent Hawryluk in fiscal 2025, including a base salary of $625,000. Disclosed compensation is on record for 3 fiscal years. P. Kent Hawryluk has spoken on 1 earnings call and 3 other investor events across 1 company, most recently for MBX Biosciences, Inc. on June 12, 2026. MBX Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at MBX Biosciences, Inc. includes Steven Hoerter (CEO and Chairman), John Smither (CFO), Ed Mathers (Board Member) and 7 others.
“to elect two Class I director nominees, Tiba Aynechi, Ph.D. and P. Kent Hawryluk, to the Company's Board of Directors, each to hold office until the Company's 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal”
“Good morning, and thank you for joining us to review the once-weekly Canbu Paratide one-year data from the Phase II Open Label Extension Study. I am Kent Harlick, President and CEO of MBX.”
“First I'd like to thank Fiona and the Jefferies team for inviting us to participate in the Jefferies Global Healthcare Conference.”
“Well, first of all, thank you, Ellie and the Barclays team for the invitation to participate in this conference. Also, a reminder to everyone that we will be making forward-looking statements and encouraging you to review our risk factors and other disclosures and our STC filings you can find on our website.”
“Today, we are thrilled to share positive top-line results from our available FASU trial. The results exceeded our expectations and reinforced the potential of once-weekly Tandu Paratide as a best-in-class treatment for hypoparathyroidism.”
Start not stated–2026-07-13
Start not stated–2026-07-13
Biotechnology · Healthcare
Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | MBX Biosciences, Inc. (MBX) | President and Chief Executive Officer | $625,000 | $2,990,867 |
| 2024 | MBX Biosciences, Inc. (MBX) | President and Chief Executive Officer | $483,300 | $2,235,317 |
| 2023 | MBX Biosciences, Inc. (MBX) | President and Chief Executive Officer | $420,000 | $4,862,064 |
